Alkermes plc has begun its Phase 3 Brilliance Studies, a three‑study program that will evaluate the oral orexin‑2 receptor agonist alixorexton in adults with narcolepsy type 1 and type 2. Each study will run for 12 weeks and compare alixorexton to placebo, with the primary endpoint set as the Maintenance of Wakefulness Test and secondary endpoints including cataplexy rates.
The Brilliance Studies are the next step after a successful Phase 2 program that earned the drug Breakthrough Therapy designation from the U.S. Food and Drug Administration for narcolepsy type 1. The program’s design—three parallel, randomized, double‑blind, placebo‑controlled trials—provides a robust assessment of efficacy and safety across the two narcolepsy subtypes, positioning alixorexton as a potential first‑in‑class treatment for a condition with significant unmet need.
Alkermes’ focus on sleep medicine has been reinforced by its 2023 acquisition of Avadel Pharmaceuticals, which added the sodium oxybate product LUMRYZ to its portfolio. The new Phase 3 program builds on that strategic foundation and expands the company’s orexin platform, which could become a key driver of future growth if the drug meets its clinical objectives.
Financially, Alkermes reported Q1 2025 revenue of $306.5 million, GAAP net income of $22.5 million, and diluted GAAP EPS of $0.13. In Q4 2025 the company posted an EPS of $0.29, exceeding revenue forecasts while maintaining a cash and investments balance of $916.2 million. These results demonstrate the firm’s capacity to fund the substantial R&D investment required for a Phase 3 program.
Management emphasized the significance of the milestone. Chief Medical Officer Craig Hopkinson said, "Building on the positive findings observed in our large phase 2 program across both narcolepsy type 1 and type 2, we are entering this pivotal stage with confidence." CEO Richard Pops added, "The strong momentum in the ALKS 2680 development program and the potential of orexin 2 receptor agonists underscore our conviction that targeting the orexin pathway can fundamentally shift treatment expectations for central disorders of hypersomnolence."
The announcement has been well received by investors, reflecting confidence in the program’s potential to address a substantial unmet medical need and to strengthen Alkermes’ position in the sleep‑medicine market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.